Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Currently, Medicare has to wait seven years after a traditional drug gets approved by the U.S. Food and Drug Administration (FDA) before it’s eligible for Medicare price negotiations. Traditional ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.